Table 3.
Cost (SD), $ | Utility (SD) | Marginal Cost-Utility Ratio,*$/QALY | |
---|---|---|---|
Histamine2-receptor antagonist | 1,195 (915) | 11.56 (0.27) | |
Proton pump inhibitor | 1,412 (760) | 11.76 (0.26) | 13,000 |
Upper gastrointestinal series | 1,516 (1065) | 11.58 (0.29) | 190,000 |
Esophagogastroduodenoscopy | 2,145 (642) | 11.61 (0.25) | 230,000 |
Dollars per additional quality-adjusted life year; all comparisons against the histamine 2-receptor antagonist alternative.